Current World Health Organization statistics show that the clinical mortality rate of tuberculosis patients can reach 1 in 10,000, and that death in tuberculosis patients is mainly due to infection by Mycobacterium tuberculosis. Mycobacterium tuberculosis consumes a large amount of energy from the body, including rich nutrition, and is a chronic wasting disease that leads to a decrease in the body’s immunity and a strong inflammatory response to tuberculosis. And the infection further aggravates and severely damages more organs in the body, such as it can involve bones, brain, reproductive system, urinary system and even cause multi-organ failure. Therefore, early standardized combined anti-tuberculosis drug treatment is needed to reduce the mortality of tuberculosis.